Lewes, DE -- (SBWire) -- 08/07/2013 --LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Opexa Therapeutics Inc (NASDAQ:OPXA), Santarus, Inc. (NASDAQ:SNTS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Opexa Therapeutics Inc (NASDAQ:OPXA) gained 122.22% recently, while trading on 20.92M shares, at the price of $2.80. The stock changed hands in a range of $2.00 to $3.70 up till now, bringing its market capitalization at about $22.78M. If we look at its trading history of the past 52 weeks, the share price suffered a low of $1.07 on Dec 28, 2012 and was moved to the maximum level of $5.19 on Feb 5, 2013. Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS).

For How Long OPXA will Fight for Profitability? Read This Trend Analysis report

Santarus, Inc. (NASDAQ:SNTS) added 8.56% recently, in the current trading session, at $27.00 with a total volume of 5.18M shares. The stock, on average, trades on a volume of 1.34M shares. It floated in a range of $26.25 to $28.10 during the recent trading session, with a beta value of 1.31. Its market capitalization now moved to about $1.75B. In the past 52 weeks, the share price has not declined below $4.82 or above $28.10. Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists.

For How Long SNTS Gloss will Attract Investors? Find out via this report

MannKind Corporation (NASDAQ:MNKD) recently recorded a gain of 3.27% and was moving within a range of $7.30 -$7.64, its current trading price is $7.59. The stock is moving up till now with a total volume of 4.28M shares, versus an average volume of 6.27M shares. The share price hit its 52-week low of $1.82 on Oct 23, 2012 and $8.33 was the best price in the same period. MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Will MNKD Continue To Move Higher? Find Out Here

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) added 3.51% in its current trading activity, bringing its market capitalization around $1.67B. The share price, after opening at $7.37, hit a high of $7.71 and hovered above $7.25, while its recent trading price was $7.67. The total number of shares changed hands during the current session up till now was 5.34M shares, as compared to average trading volume of 5.10M shares. Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors.

Why Should Investors Buy ARNA After The Recent Gain? Just Go Here and Find Out

About LeadingStockAlerts:
LeadingStockAlertsis a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/